[Effects of transdermal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group].
Pain still afflicts most cancer patients, mainly in the metastatic phases, and undertreatment is well documented. Transdermal delivery systems (TDS) could potentially have advantages over oral and parental routes, but evidence from comparative trials are scanty. In the framework of a wider initiative, an Outcome Research Study was carried out in Italy in 2006 to evaluate the effects of various analgesic options, particularly TDS Buprenorphine. Despite the limitations due to the observational design, these findings may be useful to clinicians to better judge the value of the drug under evaluation and to help researchers to design further comparative studies.
Greco
Maria Teresa
MT
Centro per la Ricerca e lo Studio del dolore (CERP), Istituto di Ricerche Farmacologiche Mario Negri, Milano. mtgreco@marionegri.it
Deandrea
Silvia
S
Corli
Oscar
O
Montanari
Mauro
M
Caraceni
Augusto
A
Apolone
Giovanni
G
D000279:Administration, Cutaneous; D000701:Analgesics, Opioid / Q000008:administration & dosage*; D002047:Buprenorphine / Q000008:administration & dosage*; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care / Q000379:methods; D010146:Pain / Q000188:drug therapy; D010147:Pain Measurement; D010166:Palliative Care / Q000379:methods; D011446:Prospective Studies; D011788:Quality of Life; D012107:Research Design; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D000701:Analgesics, Opioid; D002047:Buprenorphine